BE1016292A3 - CONNECTION AND USE IN TREATMENT. - Google Patents

CONNECTION AND USE IN TREATMENT. Download PDF

Info

Publication number
BE1016292A3
BE1016292A3 BE2004/0472A BE200400472A BE1016292A3 BE 1016292 A3 BE1016292 A3 BE 1016292A3 BE 2004/0472 A BE2004/0472 A BE 2004/0472A BE 200400472 A BE200400472 A BE 200400472A BE 1016292 A3 BE1016292 A3 BE 1016292A3
Authority
BE
Belgium
Prior art keywords
treatment
connection
pharmaceutically acceptable
epicholecalciferol
bishomo
Prior art date
Application number
BE2004/0472A
Other languages
Dutch (nl)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Application granted granted Critical
Publication of BE1016292A3 publication Critical patent/BE1016292A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Het gebruik van 1-alfa-fluoro-25-hydroxy-16,23E-dieen-26,27-bishomo-20-epicholecalciferol, of een farmaceutisch aanvaardbaar zout of farmaceutisch aanvaardbare ester daarvan, voor de fabricage van een medicament ter preventie en/of behandeling van benigne prostaathyperplasie (BPH) en daarmee samenhangende symptonen.The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol, or a pharmaceutically acceptable salt or pharmaceutically acceptable ester thereof, for the manufacture of a medicament for prevention and / or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.

BE2004/0472A 2003-09-24 2004-09-24 CONNECTION AND USE IN TREATMENT. BE1016292A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
BE1016292A3 true BE1016292A3 (en) 2006-07-04

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2004/0472A BE1016292A3 (en) 2003-09-24 2004-09-24 CONNECTION AND USE IN TREATMENT.

Country Status (12)

Country Link
EP (1) EP1673096A1 (en)
JP (2) JP2007506699A (en)
CN (1) CN100488511C (en)
BE (1) BE1016292A3 (en)
BR (1) BRPI0404050A (en)
CH (1) CH698144B1 (en)
EA (1) EA010240B1 (en)
FR (1) FR2859910B1 (en)
HK (1) HK1085373A1 (en)
NL (1) NL1027109C2 (en)
NZ (1) NZ535531A (en)
WO (1) WO2005027923A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100965205B1 (en) * 2004-10-05 2010-06-24 깃세이 야쿠힌 고교 가부시키가이샤 Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
ATE535242T1 (en) * 2004-10-06 2011-12-15 Kissei Pharmaceutical MEDICAL COMPOSITION FOR PREVENTING TRANSITION TO SURGICAL TREATMENT FOR PROSTATE HYPERTROPHY
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (en) * 2017-03-20 2018-09-21 Pierre Fabre Medicament USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
US6100294A (en) * 1997-05-16 2000-08-08 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH) 3-epi-vitamin D3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANON: "BioXell commences phase II trial of BXL - 628", DRUG NEWS & PERSPECTIVES, (MAR 2003) VOL. 16, NO. 2, PP. 122-122. PUBLISHER: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0214-0934., March 2003 (2003-03-01), XP001205124 *
BRANDL MICHAEL ET AL: "Chemical reactivity of Ro-26-9228, 1alpha-fluoro-25-hydroxy-16,23E-di ene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 10, October 2003 (2003-10-01), pages 1981 - 1989, XP002315528, ISSN: 0022-3549 *
CRESCIOLI C ET AL: "Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 591 - 603, XP009043025, ISSN: 0804-4643 *
http://www3.interscience.wiley.com/cgi-bin/abstract/104550629/ABSTRACT, Published Online 30 Jul 2003 *
MEALY N E: "BXL-628", DRUGS OF THE FUTURE 2004 SPAIN, vol. 29, no. 6, 2004, pages 629, XP009043214, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
NL1027109C2 (en) 2005-05-03
NZ535531A (en) 2006-03-31
CN1615891A (en) 2005-05-18
CN100488511C (en) 2009-05-20
NL1027109A1 (en) 2005-03-29
EA010240B1 (en) 2008-06-30
EA200401100A1 (en) 2005-04-28
JP2009035559A (en) 2009-02-19
CH698144B1 (en) 2009-05-29
FR2859910A1 (en) 2005-03-25
EP1673096A1 (en) 2006-06-28
FR2859910B1 (en) 2006-04-28
WO2005027923A1 (en) 2005-03-31
HK1085373A1 (en) 2006-08-25
BRPI0404050A (en) 2005-06-14
JP2007506699A (en) 2007-03-22

Similar Documents

Publication Publication Date Title
HUP0100586A2 (en) Pharmaceutical compositions treating lower urinary tract symptoms
LU93321I2 (en) IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
WO2006015263A3 (en) Lonidamine analogs
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
MXPA05010819A (en) The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE538103T1 (en) QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MY137757A (en) Therapeutic treatment
IL180979A (en) Isoindoline compounds and use thereof
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2003011117A3 (en) Methods and compositions for treating and preventing distal bowel lesions
RS54185B1 (en) Use of 24-norudca
HK1085373A1 (en) Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms
TN2009000135A1 (en) Use of modified cyclosporins
EA200970353A1 (en) COMBINED MEDICINE
PT1713438E (en) Medicinal soap
NL1025844A1 (en) Benzopyran compounds for use in the treatment and prevention of inflammatory diseases.
GB201115757D0 (en) Formulation for the treatment of benign prostate hyperplasia
MX2009009230A (en) Use of silodosin in a once daily administration for treating benign prostatic hyperplasia.
AU2003219573A1 (en) Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20100930